RecruitingNot Applicable

Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse

France50 participantsStarted 2025-03-22

Plain-language summary

B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.

Who can participate

Age range0 Years – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Under 18 years * With established diagnosis of B-ALL * Initial diagnosis made in the investigating centre * Having received oral and written information about the protocol, or oral only if the patient is unable to read. * Having signed a consent form if the patient is capable of giving informed written consent. * Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent. * Beneficiary of a social security scheme Exclusion Criteria: * Isolated extramedullary involvement at inclusion * Patient of childbearing age without effective contraception. * Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.

What they're measuring

Non coding RNA network in CD9 regulation

Timeframe: 5 years

Trial details

NCT IDNCT06649253

SponsorRennes University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2035-04

Contact for this trial

Elie COUSIN, Md

299284321 elie.cousin@univ-rennes.fr

View on ClinicalTrials.gov More Leukemia, Lymphoblastic, Acute, Pediatric trials